DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Consensus Recommendation of “Hold” from Brokerages

DiaSorin S.p.A. (OTCMKTS:DSRLF) has received an average recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company.

DSRLF has been the topic of a number of research reports. UBS Group cut shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Piper Sandler assumed coverage on shares of DiaSorin in a research report on Thursday, June 11th. They set a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft downgraded shares of DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. Finally, Zacks Research raised shares of DiaSorin to a “hold” rating in a research note on Tuesday, May 12th.

DiaSorin Stock Performance

Shares of DSRLF stock opened at $81.00 on Friday. DiaSorin has a fifty-two week low of $66.50 and a fifty-two week high of $100.00. The business has a fifty day simple moving average of $73.79 and a 200-day simple moving average of $75.95.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.